# Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

> **NCT02252146** · PHASE1,PHASE2 · COMPLETED · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** IMO-8400

## Key facts

- **NCT ID:** NCT02252146
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252146, "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02252146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*